Explore the words cloud of the REUSE4MALARIA project. It provides you a very rough idea of what is the project "REUSE4MALARIA" about.
The following table provides information about the project.
Coordinator |
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Organization address contact info |
Coordinator Country | Portugal [PT] |
Total cost | 145˙500 € |
EC max contribution | 145˙500 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2015-PoC |
Funding Scheme | ERC-POC |
Starting year | 2016 |
Duration (year-month-day) | from 2016-12-01 to 2018-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES | PT (LISBOA) | coordinator | 145˙500.00 |
Malaria is a serious parasitic disease afflicting 198 million people in 2013, with an estimated death toll of approximately 600 000. Approximately half the world’s population is at risk of malaria. So far there is no cure/vaccine against malaria and current chemoprotective treatments have shortcomings, such as: 1) Limited Number of Drugs effective against malaria parasites; 2) Adverse Side Effects (observed in 32% to 44% of users); 3) Parasite Resistance to most of the drugs used for prevention and treatment; and 4) Limited Use (restrictions on age, genetic traits, pregnancy, etc). Our ERC-funded research uncovered a novel mechanism of action that can be targeted for malaria chemoprotection, with fewer side effects and reduced propensity to generate parasite resistance, on which we filed for IP protection. Furthermore, we have identified a set of likely drug candidates already validated in the clinic, which are likely candidates for malaria chemoprotection. In fact, our preliminary data indicates that a known anti-diabetic drug significantly affects parasite growth. We are seeking funding to initiate pre-clinical studies for repurposing this drug for malaria chemoprotection. This PoC funding will allow us to complete the following aims: 1) in vitro profiling to define therapeutic dose for malaria chemoprotection; 2) in vivo profiling to perform efficacy and toxicity studies; 3) further define IP Strategy; 4) draft early stage Regulatory Approval Roadmap; 5) conduct Market Analysis and develop a Business Case.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REUSE4MALARIA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "REUSE4MALARIA" are provided by the European Opendata Portal: CORDIS opendata.